Literature DB >> 6306286

Ketoconazole: a novel and rapid treatment for advanced prostatic cancer.

J Trachtenberg, N Halpern, A Pont.   

Abstract

Ketoconazole is an orally administered broad-spectrum antifungal agent that acts through the inhibition of the steroid synthetic pathways. At high doses in humans ketoconazole can lower rapidly serum testosterone and maintain it in the castrate range with frequent administration. This property suggested that ketoconazole might be useful in the treatment of prostatic cancer. We report a case of prostatic cancer in which ketoconazole resulted in rapid and sustained reduction in serum androgens as well as rapid induction of a clinical remission. Ketoconazole may be a valuable agent in the treatment of prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306286     DOI: 10.1016/s0022-5347(17)51007-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.

Authors:  David R Yates; Morgan Rouprêt
Journal:  World J Urol       Date:  2011-11-23       Impact factor: 4.226

2.  Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.

Authors:  Charlie Fehl; Caleb D Vogt; Rahul Yadav; Kelin Li; Emily E Scott; Jeffrey Aubé
Journal:  J Med Chem       Date:  2018-05-24       Impact factor: 7.446

Review 3.  Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer.

Authors:  Trevor M Penning
Journal:  Vitam Horm       Date:  2018-02-24       Impact factor: 3.421

Review 4.  Hormonal aspects of prostatic cancer: a review.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1985-02       Impact factor: 5.344

Review 5.  The endocrine effects of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

6.  Treatment of advanced carcinoma of the prostate.

Authors:  G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

7.  Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.

Authors:  J M Allen; D J Kerle; H Ware; A Doble; G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

Review 8.  Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.

Authors:  Paul J Toren; Martin E Gleave
Journal:  Asian J Androl       Date:  2013-04-15       Impact factor: 3.285

9.  Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer.

Authors:  Kiranmayi Tadi; Badithe T Ashok; Yuangen Chen; Debabrata Banerjee; Barbara Wysocka-Skrzela; Jerzy Konopa; Zbigniew Darzynkiewicz; Raj K Tiwari
Journal:  Cancer Biol Ther       Date:  2007-07-24       Impact factor: 4.742

10.  17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

Authors:  Robert D Bruno; Tony D Gover; Angelika M Burger; Angela M Brodie; Vincent C O Njar
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.